Altogether, our findings showed that the SRSF1 expression level could affect tumor immune characteristics via infiltrating immune cells, TME, checkpoint markers, and immune-related genes, thereby determining the prognosis of patients with MM. This evidence concerns the gene SRSF1 and Miyoshi myopathy.